Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 22, Pages -Publisher
MDPI
DOI: 10.3390/ijms222212142
Keywords
RAS; KRAS mutant; KRAS inhibitors; targeted protein degradation (TPD); drug resistance; PROTAC
Funding
- National Research Foundation of Korea [NRF-2018R1D1A1A02086100, 2021R1A2C1012280, 2020R1A6A1A03043708]
- National Research Foundation of Korea [2020R1A6A1A03043708, 2021R1A2C1012280] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The study explores methods for treating cancers caused by KRAS mutations, including controlling the activity of RAS pathway proteins, small-molecule inhibitors, and targeted protein degradation strategies. These novel approaches are expected to provide promising therapeutic options for tumor patients with KRAS mutations.
Drug resistance continues to be a major problem associated with cancer treatment. One of the primary causes of anticancer drug resistance is the frequently mutated RAS gene. In particular, considerable efforts have been made to treat KRAS-induced cancers by directly and indirectly controlling the activity of KRAS. However, the RAS protein is still one of the most prominent targets for drugs in cancer treatment. Recently, novel targeted protein degradation (TPD) strategies, such as proteolysis-targeting chimeras, have been developed to render undruggable targets druggable and overcome drug resistance and mutation problems. In this study, we discuss small-molecule inhibitors, TPD-based small-molecule chemicals for targeting RAS pathway proteins, and their potential applications for treating KRAS-mutant cancers. Novel TPD strategies are expected to serve as promising therapeutic methods for treating tumor patients with KRAS mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available